US equities
|
MU
$1,044.89
▼-3.96%
NVDA
$230.85
▼-2.79%
SNDK
$1,615.83
▼-4.53%
AMD
$620.58
▼-3.91%
INTC
$107.14
▼-5.29%
SPCX
$162.32
▼-3.15%
META
$718.86
▼-0.34%
PLTR
$197.06
▲+1.51%
MU
$1,044.89
▼-3.96%
NVDA
$230.85
▼-2.79%
SNDK
$1,615.83
▼-4.53%
AMD
$620.58
▼-3.91%
INTC
$107.14
▼-5.29%
SPCX
$162.32
▼-3.15%
META
$718.86
▼-0.34%
PLTR
$197.06
▲+1.51%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Polyrizon Ltd. - Ordinary Shares
(NQ:
PLRZ
)
8.921
-0.229 (-2.50%)
Delayed Quote
Updated: 2:03 PM EDT, Oct 8, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Polyrizon Ltd. - Ordinary Shares
< Previous
1
2
3
Next >
Polyrizon Files for U.S. Patent Application to Expand IP Moat Around Intranasal Drug-Delivery Platform
October 05, 2026
From
Polyrizon Ltd.
Via
GlobeNewswire
Polyrizon Enrolls First Patient in U.S. Clinical Study of NASARIX (PL-14) Allergy Blocker
September 22, 2026
From
Polyrizon Ltd.
Via
GlobeNewswire
Polyrizon Ltd. Announces Closing of $4.0 Million Registered Direct Offering and Private Placement
September 04, 2026
From
Polyrizon Ltd.
Via
GlobeNewswire
Polyrizon Ltd. Announces $4.0 Million Registered Direct Offering and Private Placement
September 03, 2026
From
Polyrizon Ltd.
Via
GlobeNewswire
Polyrizon Completes All Five U.S. Site Contracts for NASARIX™ First-in-Human Allergy Study
September 02, 2026
From
Polyrizon Ltd.
Via
GlobeNewswire
Polyrizon Completes Clinical Site Network for NASARIX™ Study and Advances Toward Patient Enrollment
August 20, 2026
From
Polyrizon Ltd.
Via
GlobeNewswire
Polyrizon Announces Successful Results for NASARIX™ Biocompatibility Program, Supporting Advancement Towards First in Human Clinical Trial
July 02, 2026
From
Polyrizon Ltd.
Via
GlobeNewswire
Polyrizon Makes Strong Progress: Receives Central IRB Approval for its Allergy Blocker Clinical Trial
June 29, 2026
From
Polyrizon Ltd.
Via
GlobeNewswire
Polyrizon Receives Notice of U.S. Patent Publication for Mucoadhesive Drug Delivery Platform
June 17, 2026
From
Polyrizon Ltd.
Via
GlobeNewswire
Polyrizon Advances NASARIX™ Development with Key Human Study to Characterize Nasal Residence Time and Support FDA Regulatory Pathway
June 15, 2026
From
Polyrizon Ltd.
Via
GlobeNewswire
Polyrizon Receives Notice of European Patent Publication for Innovative Mucoadhesive Nasal Drug Delivery Technology
June 10, 2026
From
Polyrizon Ltd.
Via
GlobeNewswire
Polyrizon Makes Strong Clinical Progress: Secures Three U.S. Sites for NASARIX™ Trial
June 08, 2026
From
Polyrizon Ltd.
Via
GlobeNewswire
Polyrizon Advances Towards Human Clinical Trials: Secures First U.S. Clinical Site for NASARIX™ Allergy Blocker Clinical Trial
May 13, 2026
From
Polyrizon Ltd.
Via
GlobeNewswire
Polyrizon Announces U.S. Patent Expansion for Its Intranasal Drug Delivery Platform
May 04, 2026
From
Polyrizon Ltd.
Via
GlobeNewswire
Polyrizon Announces Filing of European Patent Application for Its Breakthrough Drug Delivery Platform
April 27, 2026
From
Polyrizon Ltd.
Via
GlobeNewswire
TechMediaBreaks – Polyrizon Ltd. (NASDAQ: PLRZ) Closes $3.5 Million Registered Direct Offering and Concurrent Private Placement
April 15, 2026
Via
Investor Brand Network
Polyrizon Ltd. Announces $3.5 Million Registered Direct Offering and Private Placement
April 07, 2026
From
Polyrizon Ltd.
Via
GlobeNewswire
Polyrizon Provides 2025 and Recent Highlights
March 26, 2026
Company Concluded 2025 with Robust Cash Position, Debt-Free Balance Sheet and Significant Pipeline Achievements
From
Polyrizon Ltd.
Via
GlobeNewswire
Polyrizon Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2025
March 25, 2026
From
Polyrizon Ltd.
Via
GlobeNewswire
Polyrizon Intends to Acquire up to 20% Stake in Colugo, Developer of Advanced eVTOL Drones for Defense and Urban Air Mobility Applications
March 24, 2026
From
Polyrizon Ltd.
Via
GlobeNewswire
Polyrizon Signs an Agreement with Leading Global Preclinical CRO as Part of Clinical Development Program
March 17, 2026
From
Polyrizon Ltd.
Via
GlobeNewswire
Polyrizon Announces GMP Manufacturing of Clinical Trial Material (CTM) with Eurofins CDMO AmatsiAquitaine S.A.S for Planned U.S. Clinical Study
March 10, 2026
From
Polyrizon Ltd.
Via
GlobeNewswire
Polyrizon Announces Successful Study of its Naloxone Formulation Demonstrating Enhanced Nasal Deposition Profile Versus Commercial Reference Product
February 26, 2026
From
Polyrizon Ltd.
Via
GlobeNewswire
Polyrizon Intends to Secure Controlling Stake in Profitable Private Jet Operator
February 10, 2026
From
Polyrizon Ltd.
Via
GlobeNewswire
Polyrizon Signs an Agreement to Develop Intranasal Proprietary Non-Hallucinogenic Neuroplastogen Formulation
February 06, 2026
From
Polyrizon Ltd.
Via
GlobeNewswire
Clearmind Medicine Enters into Development Agreement to Advance Intranasal Formulation for its Proprietary Non-Hallucinogenic Neuroplastogen MEAI
February 06, 2026
From
Clearmind Medicine Inc.
Via
GlobeNewswire
Polyrizon Intends to Acquire 51% Stake in Global Private Aviation Company
February 04, 2026
From
Polyrizon Ltd.
Via
GlobeNewswire
Polyrizon Advances Regulatory Path with Initiation of Usability Study Program for NASARIX™ Allergy Blocker
January 22, 2026
From
Polyrizon Ltd.
Via
GlobeNewswire
Polyrizon to Explore Revenue-Generating Investment Opportunities in High-Growth Sectors, Leveraging Strong Cash Position and Debt-Free Balance Sheet
January 13, 2026
From
Polyrizon Ltd.
Via
GlobeNewswire
Polyrizon Completes Branding Process for PL-14 Allergy Blocker with Brand Name NASARIX™
January 08, 2026
From
Polyrizon Ltd.
Via
GlobeNewswire
< Previous
1
2
3
Next >
